United States - English - NLM (National Library of Medicine)

mallinckrodt nuclear medicine llc - sodium iodide i-131 (unii: 29vco8achh) (iodide ion i-131 - unii:4gc1foq22u) - iodide ion i-131 1 mci in 1 ml

United States - English - NLM (National Library of Medicine)

mallinckrodt nuclear medicine llc - sodium iodide i-131 (unii: 29vco8achh) (iodide ion i-131 - unii:4gc1foq22u) - iodide ion i-131 5 mci in 1 ml

United States - English - NLM (National Library of Medicine)

mallinckrodt, inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 5 mg in 5 ml

United States - English - NLM (National Library of Medicine)

mallinckrodt inc (brand pharmaceuticals) - baclofen (unii: h789n3fke8) (baclofen - unii:h789n3fke8) - baclofen 50 ug in 1 ml - gablofen is indicated for use in the management of severe spasticity in adult and pediatric patients age 4 years and above. patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. for spasticity of spinal cord origin, chronic infusion of gablofen via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable cns side effects at effective doses. patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. gablofen is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only with the medtronic synchromed® ii programmable pump or other pumps labeled for intrathecal administration of gablofen  [see clinical studies (14)] . prior to implantation of a device for chronic intrathec

United States - English - NLM (National Library of Medicine)

mallinckrodt hospital products inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - acetaminophen 10 mg in 1 ml - ofirmev® (acetaminophen) injection is indicated for - the management of mild to moderate pain in adult and pediatric patients 2 years and older - the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older - the reduction of fever in adult and pediatric patients. acetaminophen is contraindicated: - in patients with known hypersensitivity to acetaminophen or to any of the excipients in the intravenous formulation. - in patients with severe hepatic impairment or severe active liver disease [see warnings and precautions (5.1)] . risk summary published epidemiological studies with oral acetaminophen use during pregnancy have not reported a clear association with acetaminophen use and birth defects, miscarriage, or adverse maternal or fetal outcomes [see data] . animal reproduction studies have not been conducted with iv acetaminophen. reproductive and developmental studies in rats and mice from the published literature identified adverse events at

Singapore - English - HSA (Health Sciences Authority)

covidien private limited - anaesthesiology - intended for oral or nasal intubation and are indicated for airway management. although uncuffed tracheal tubes are ordinarily used in pediatric airway management, in some cases (e.g. pulmonary function testing or aspiration protection), use of a small diameter cuffed tracheal tube may be indicated. the proper designation, "oral", "nasal", or "oral/nasal" is printed on the tracheal tube.

United States - English - NLM (National Library of Medicine)

mallinckrodt hospital products inc. - terlipressin (unii: 7z5x49w53p) (terlipressin - unii:7z5x49w53p) - terlivaz is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. limitation of use patients with a serum creatinine > 5 mg/dl are unlikely to experience benefit. terlivaz is contraindicated in patients experiencing hypoxia or worsening respiratory symptoms. terlivaz is contraindicated in patients with ongoing coronary, peripheral or mesenteric ischemia. risk summary based on findings from the published literature and on its mechanism of action, terlivaz may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . in small, published studies, administration of a single intravenous dose of terlipressin to pregnant women during the first trimester induced uterine contractions and endometrial ischemia. the limited published data are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. if terlivaz is used during pregnancy, the patient should be informed of the potential risk to

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - cephalexin - oral solution/suspension - cephalexin antibiotic active 150.0 mg/g - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - infections of the respiratory tract | infections of the skin | infections of the urogenital tract | localised infections in soft tissue | abscesses | acute respiratory infections | anal sacculitis | bronchiseptica | bronchitis | cystitis | fungal | gingivitis | gram negative bacteria | gram positive bacteria | metritis | nephritis | pharyngitis | pneumonia | post-parturient infections | pyoderma | septicaemia | tonsillitis | yeast

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - temazepam (unii: chb1qd2qss) (temazepam - unii:chb1qd2qss) - temazepam capsules usp are indicated for the short-term treatment of insomnia (generally 7 to 10 days). for patients with short-term insomnia, instructions in the prescription should indicate that temazepam capsules usp should be used for short periods of time (7 to 10 days). the clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. benzodiazepines may cause fetal harm when administered to a pregnant woman. an increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. transplacental distribution has resulted in neonatal cns depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. reproduction studies in animals with temazepam were performed in rats and rabbits. in a perinatal-postnatal study in rats, oral doses of 60 mg/kg/da

Ireland - English - HPRA (Health Products Regulatory Authority)

mallinckrodt uk limited - iotalamate meglumine - solution for injection - 280 mg/ml